Placebo News and Research

RSS

HPV vaccine can prevent 90% of genital warts in men: Study

The vaccine for human papillomavirus can prevent 90 percent of genital warts in men when offered before exposure to the four HPV strains covered by the vaccine, according to a new multi-center study led by H. Lee Moffitt Cancer Center and UCSF.

4 Feb 2011

Merck reports GAAP net income of $861 million for 2010

Merck, known as MSD outside the United States and Canada, today announced financial results for the fourth quarter and full year of 2010. The company reported non-GAAP (generally accepted accounting principles) earnings per share (EPS) for the fourth quarter of $0.88, which excludes purchase accounting adjustments, restructuring costs and merger-related expenses.

4 Feb 2011

Positive results from KYTHERA's ATX-101 Phase IIb study for reduction of submental fat

KYTHERA Biopharmaceuticals, Inc. today announced that it has successfully completed a third Phase II clinical study with ATX-101, a first-in-class adipolytic agent that is under investigation for the reduction of submental ('under-the-chin') fat.

4 Feb 2011

Bayer HealthCare's regorafenib receives orphan drug status for GIST treatment

Bayer HealthCare Pharmaceuticals Inc. announced today that its investigational compound regorafenib has been granted orphan drug status for the treatment of patients with gastrointestinal stromal tumors by the U.S. Food and Drug Administration.

4 Feb 2011

CVBT seeks FDA 'fast track' designation for CVBT-141B to treat ischemic diabetic wounds

CardioVascular BioTherapeutics, Inc. today announced it has submitted an application to the U.S. FDA to obtain "fast track" designation for CVBT-141B, its biological therapy to treat ischemic diabetic wounds based on the active ingredient fibroblast growth factor-1 (FGF-1).

4 Feb 2011

Positive results from Derma Sciences' Phase 2 trial with DSC127 in patients with diabetic foot ulcers

Derma Sciences, Inc., a medical device and pharmaceutical company focused on advanced wound care, today announced positive results from its Phase 2 clinical trial with DSC127 in patients with diabetic foot ulcers, including meeting the trial's primary endpoint, the proportion of study ulcers healed by 12 weeks as defined by 100% epithelialized with no drainage, as well as all secondary endpoints measured at this time.

3 Feb 2011

Merck announces publication of GARDASIL pivotal Phase III study data in NEJM

Merck announced today that data from the pivotal Phase III study with GARDASIL in males were published in the February 3 issue of the New England Journal of Medicine.

3 Feb 2011

ImmunoCellular Therapeutics initiates enrollment in ICT-107 Phase II trial for GBM

ImmunoCellular Therapeutics, Ltd., a biotechnology company that is developing immune-based therapies for the treatment of various forms of cancer, announced today that the first patient has been enrolled in its Phase II trial of ICT-107 at the New Jersey Neuroscience Institute at JFK Medical Center. ICT-107 is the company's dendritic cell based cancer vaccine candidate for the treatment of glioblastoma multiforme (GBM).

3 Feb 2011

Shire announces Health Canada's approval of VYVANSE for treatment of ADHD in adolescents and adults

Shire plc, the global specialty biopharmaceutical company, announces that Health Canada has approved VYVANSE® (lisdexamfetamine dimesylate capsules) for the treatment of attention deficit hyperactivity disorder (ADHD) in adolescents and adults.

2 Feb 2011

DARA BioSciences' KRN5500 Phase 2 study in advanced cancer selected for presentation at ADEPT 2011

The Company announced that the University of Rochester in concert with ADEPT has selected the study results from the KRN5500 Phase 2 study to be presented at its March 25-26, 2011 conference. The presentation is entitled, "Management of Placebo Response in a Randomized Trial of KRN5500 in Patients with Neuropathic Pain and Cancer."

2 Feb 2011

Nitrate boosts efficiency of mitochondria

The spinach-eating cartoon character Popeye has much to teach us, new research from the Swedish medical university Karolinska Institutet shows. The muscles' cellular power plants - the mitochondria - are boosted by nitrate, a substance found in abundance in vegetables such as lettuce, spinach and beetroot.

2 Feb 2011

Daily probiotic may help prevent upper respiratory tract infections in athletes: Research

Researchers at Loughborough University have revealed that a simple, daily probiotic might help prevent athletes catching colds during their training and competition.

2 Feb 2011

BioMarin commences GALNS Phase 3 trial in patients with Morquio A Syndrome

BioMarin Pharmaceutical announced today that it has initiated a pivotal Phase 3 trial for N-acetylgalactosamine 6-sulfatase, intended for the treatment of the lysosomal storage disorder Mucopolysaccharidosis Type IVA, also called Morquio A Syndrome.

1 Feb 2011

Positive interim results from H5N1 Avian Influenza VLP vaccine Phase II human clinical trial

Medicago, a biotechnology company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles, today reported positive interim results from a Phase II human clinical trial with its H5N1 Avian Influenza VLP vaccine candidate.

1 Feb 2011

Positive interim results from Medicago's Phase II clinical trial of H5N1 Avian Influenza VLP vaccine

Medicago Inc. a biotechnology company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today reported positive interim results from a Phase II human clinical trial with its H5N1 Avian Influenza VLP vaccine candidate ("H5N1 vaccine"). The vaccine was found to be safe, well tolerated and also induced a solid immune response.

1 Feb 2011

Orexigen, Takeda announce FDA's issue of complete response letter for Contrave NDA

Orexigen® Therapeutics, Inc. and Takeda Pharmaceutical Company Limited announced today that the United States Food and Drug Administration (FDA) has issued a complete response letter dated January 31, 2011 regarding the New Drug Application for Contrave® (naltrexone HCl/bupropion HCl) extended-release tablets for the treatment of obesity, including weight loss and maintenance of weight loss.

1 Feb 2011

Elsevier announces publication of two position statements from EMAS in Maturitas journal

Elsevier announced today the publication of two further important position statements from the European Menopause and Andropause Society in the journal Maturitas on common management problems in the post-reproductive health of women.

1 Feb 2011

Circassia Phase II clinical trial confirms safety profile of ToleroMune cat allergy treatment

Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced that the company's ToleroMune(R) cat allergy treatment significantly reduced patients' symptoms in a recently completed, large-scale phase II clinical trial. The study also confirmed the treatment's highly favourable safety profile.

1 Feb 2011

Highly favorable final results from ERGOFLEX initial clinical study for joint pain relief

OXIS International, today announced highly favorable final results from an initial clinical study to assess the beneficial effects of its patent-pending ERGOFLEX joint health formula, launched commercially in December 2010.

1 Feb 2011

Positive results from NRM8499 phase I clinical study in patients with Alzheimer's disease

BELLUS Health announced today the results of the phase I clinical study for NRM8499, a prodrug of tramiprosate, intended for the treatment of Alzheimer's disease.

1 Feb 2011

Placebo News and Research

HPV vaccine can prevent 90% of genital warts in men: Study

Merck reports GAAP net income of $861 million for 2010

Positive results from KYTHERA's ATX-101 Phase IIb study for reduction of submental fat

Bayer HealthCare's regorafenib receives orphan drug status for GIST treatment

CVBT seeks FDA 'fast track' designation for CVBT-141B to treat ischemic diabetic wounds

Positive results from Derma Sciences' Phase 2 trial with DSC127 in patients with diabetic foot ulcers

Merck announces publication of GARDASIL pivotal Phase III study data in NEJM

ImmunoCellular Therapeutics initiates enrollment in ICT-107 Phase II trial for GBM

Shire announces Health Canada's approval of VYVANSE for treatment of ADHD in adolescents and adults

DARA BioSciences' KRN5500 Phase 2 study in advanced cancer selected for presentation at ADEPT 2011

Nitrate boosts efficiency of mitochondria

Daily probiotic may help prevent upper respiratory tract infections in athletes: Research

BioMarin commences GALNS Phase 3 trial in patients with Morquio A Syndrome

Positive interim results from H5N1 Avian Influenza VLP vaccine Phase II human clinical trial

Positive interim results from Medicago's Phase II clinical trial of H5N1 Avian Influenza VLP vaccine

Orexigen, Takeda announce FDA's issue of complete response letter for Contrave NDA

Elsevier announces publication of two position statements from EMAS in Maturitas journal

Circassia Phase II clinical trial confirms safety profile of ToleroMune cat allergy treatment

Highly favorable final results from ERGOFLEX initial clinical study for joint pain relief

Positive results from NRM8499 phase I clinical study in patients with Alzheimer's disease

Industry Focus eBook - Neurology/Neuroscience - 2nd edition eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News